Top Injectable Manufacturer in Belize - Reliable Pharmaceutical Solutions
Why Farbe Firma is the Leading Injectable Manufacturer in Belize
Last Updated: 15 September 2026
TL;DR: Belize has no standalone medicines agency. Authorisation sits with the Director of Health Services inside the Ministry of Health and Wellness, and the operative instrument is the Food and Drugs (Registration, Licensing and Inspection) Regulations 2017, S.I. No. 54 of 2017. That instrument requires genuine product registration rather than a bare import permit, and it names no approved countries and no recognised regulators at all, so an Indian WHO-GMP file is admissible on its face. The lists that do exclude India belong to the regional CARPHA shortcut and to PAHO-funded procurement, not to Belizean law. Farbe Firma Pvt Ltd manufactures over 100 sterile injectables under WHO-GMP in ISO Class 5 cleanrooms in Gujarat, India, and supplies more than 30 countries.
Key Takeaways
Belize registers medicines under S.I. No. 54 of 2017. A product licence is mandatory and commercialising a drug without one carries a fine of up to $10,000. The orphan-drug route in regulation 5 is the only place an import authorisation replaces registration.
S.I. No. 54 of 2017 contains no list of approved countries, reference authorities or recognised GMP-certificate issuers. It asks for a valid GMP certificate, a WHO-model CPP and a certificate from the competent authority in the country of origin, and is country-agnostic on its face.
The real trap is regulation 8(1): a Belize product licence expires with whichever of the GMP certificate or the CPP expires first, and regulation 8(3) requires cancellation where renewal is not filed six months ahead. Belize renewals run on the Indian certificate calendar.
CARPHA's Caribbean Regulatory System and the PAHO Strategic Fund are the channels closed to a CDSCO-only file. Both naming documents were read in full and CDSCO appears in neither.
Introduction: What an Injectable Manufacturer in Belize Actually Has to Clear
Belize is a market of 422,924 people on World Bank 2025 data, with current health expenditure of USD 309 per capita and 4.15 percent of GDP in 2023, out-of-pocket spending at 26.8 percent, life expectancy of 73.7 years in 2024 and tuberculosis incidence of 34 per 100,000 in 2024. Belize-reported imports of pharmaceutical products from India ran at USD 1.86 million in 2022, USD 2.67 million in 2023 and USD 1.63 million in 2024. Those figures set the commercial scale. They are not what decides whether an Indian injectable can lawfully be sold there.
That is decided by one statutory instrument: the Food and Drugs (Registration, Licensing and Inspection) Regulations 2017, made on 25 July 2017 and gazetted on 29 July 2017 under the Food and Drugs Act, Chapter 291, as amended by Act No. 11 of 2017. Belize has no standalone medicines regulator. The competent authority defined by the regulations is the Director of Health Services or his nominee in the Ministry of Health and Wellness, working through the Drug Inspectorate Unit. Two practical points follow. The Belize Agricultural Health Authority does not regulate human medicines; its remit is plant, animal and food safety, and the single pharmaceutical reference in its Act sits inside the definition of an animal product. And because the Ministry rebuilt its website as a placeholder page in June 2025, current forms and fee confirmations are realistically obtained by writing to the Drug Inspectorate Unit rather than by download.
What Sets a World-Class Injectable Manufacturer in Belize Apart
A serious supplier is separated from an ordinary one by what it can put in the file on day one. Regulation 4(1) asks for a valid GMP certificate; a WHO-model Certificate of a Pharmaceutical Product, or a Certificate of Free Sale where the country of origin is outside the WHO certification scheme; a valid certificate from the competent health authority in the country of origin; an original certificate of analysis from the manufacturer's own quality control laboratory; a summary of product characteristics with finished samples, labels, primary, secondary and external packaging and the package insert; pharmacological information; and an environmental risk assessment for hormones, antineoplastics and radiopharmaceuticals. Regulation 4(2) requires every document in English, or with an English translation attached to the original.
Note what that list does not contain. There is no schedule of approved countries, no roster of recognised regulators and no geographic restriction anywhere in the instrument, including both of its Forms and both of its Schedules. The grounds for refusal in regulation 6(4) are applicant delay, an unfavourable risk-benefit balance, insufficiently justified efficacy, compositional or quality failure, erroneous information, and non-compliance with the Food and Drugs, Antibiotics, Chemists and Druggists or Misuse of Drugs Acts. None of them is country-based. A CDSCO-issued WHO-GMP certificate and CoPP are admissible on the face of the regulations, and that is worth stating plainly because it is the opposite of the position in several neighbouring markets.
Quality Systems Behind Every Batch Shipped to Belize
Farbe Firma manufactures more than 100 sterile injectables at a WHO-GMP certified facility in Gujarat, India, with aseptic filling in ISO Class 5 environments and supply into more than 30 countries. The quality system behind a Belize consignment is the one that supports our CTD and ACTD dossiers elsewhere: validated aseptic process simulations, routine environmental monitoring, HPLC and GC assay and related-substance methods, Karl Fischer moisture determination, LAL bacterial endotoxin testing, container closure integrity testing, and ICH Q1A stability programmes with photostability under ICH Q1B.
On stability an honest word is owed. WHO's stability-conditions table, in its March 2021 update, lists Belize at 30 degrees Celsius and 65 percent relative humidity. But that entry is bracketed and carries footnote 3, which means it was supplied by the IFPMA from climate literature rather than confirmed by a Belizean authority. S.I. No. 54 of 2017 specifies no stability conditions at all, and no Belize or CARICOM guidance assigning a zone was found. We therefore hold long-term data at Zone IVa conditions as a matter of prudence, and we say that it is prudence rather than a notified national requirement.
Why Farbe Firma is the Trusted Injectable Manufacturer in Belize for Global Buyers
The most expensive mistake in a Belize file is not a technical deficiency, it is a calendar. Regulation 8(1) provides that a product licence is valid until the expiration date of the GMP certificate or the Certificate of a Pharmaceutical Product, whichever expires first. There is no fixed term. Renewal must be filed six months before that date, and regulation 8(3) requires the authority to cancel a registration where it is not. For an Indian manufacturer this means the lifespan of a Belize registration is set by the shortest-dated Indian certificate in the file, and the renewal clock has to be run from the CDSCO calendar rather than from a Belize anniversary. We manage that clock with our partners rather than leaving it with the importer.
The second thing we bring is a clear-eyed view of which doors are shut. CARPHA's Caribbean Regulatory System issues a recommendation, not an authorisation, since only a sovereign state authorises for its own market, and Belize is one of six CARICOM states that conduct marketing authorisation at all. But CRS reviews only products that already hold a marketing authorisation from a listed reference authority, or that are WHO-prequalified. The naming document was read in full in both its December 2017 and its 20 November 2020 versions and searched for India, Indian, CDSCO and Central Drugs: zero occurrences in each. WHO-GMP is not an eligibility route there. The same holds for PAHO-funded procurement, whose criteria admit WHO Prequalification, stringent regulatory authorities, or the eight Americas-only national authorities of regional reference. CDSCO is none of the three.
What follows is a sequencing recommendation rather than a discouragement. The national door in Belize is open on Indian paperwork today; the regional shortcut is not. A CARPHA-archived dataset of recommended products, last modified in 2022 and therefore not a current picture, indicates that a large majority of recommended products carried Indian marketing authorisation holders, and that they reached CRS not through CDSCO but through a Chilean or Colombian marketing authorisation obtained first. That is a route we can plan with a buyer. One verified negative is worth recording alongside it: India's own bilateral brief for Belize, as on 15 July 2026, names a single agreement, on visa exemption, and no pharmaceutical, GMP-recognition or pharmacopoeia instrument at all. Neither Belize nor India appears on any PIC/S list.
Explore Farbe Firma: Products / Global Reach / About Us
Frequently Asked Questions (FAQ)
Does Belize require product registration, or only an import permit?
Registration. Regulation 3(1) of S.I. No. 54 of 2017 prohibits commercialising a drug without registration and a product licence, with a fine of up to $10,000. A separate facility licence is required for the importer, with a mandatory pre-licence inspection. The only place an import authorisation replaces registration is regulation 5, for orphan drugs. Transitional grandfathering ended on 31 October 2017 and is not available to a new entrant.
Is India on a Belize list of approved countries?
There is no such list. S.I. No. 54 of 2017 was read in full, including both Forms and both Schedules, and it names no approved countries, no reference authorities and no recognised GMP-certificate issuers. India is therefore not excluded by Belizean law. Where India's absence is verified is in the CARPHA reference-authority list and in PAHO procurement eligibility, neither of which is Belize's national gate. No amending instrument to S.I. No. 54 of 2017 was found, but that search was not exhaustive.
What dossier format does Belize accept - CTD, ACTD or eCTD?
The regulations do not say. S.I. No. 54 of 2017 prescribes Form 1 and a list of documents and is silent on CTD, ACTD and eCTD, and no Ministry guidance on format was retrievable while its website stands as a placeholder. Farbe Firma maintains CTD and ACTD-ready dossiers and supplies the regulation 4(1) documents in the Ministry's own format. We recommend confirming the format with the Drug Inspectorate Unit before compiling.
What does registration cost, and how long does a Belize licence last?
The instrument sets $100 per drug per importer for registration, $50 for an amendment and $50 for renewal, with facility fees including $550 for an importer of drugs and $5,000 for a manufacturing plant. Those figures come from an OCR-scanned gazette copy and should be confirmed against a clean copy before budgeting. The licence has no fixed term: under regulation 8(1) it runs to the earlier expiry of the GMP certificate or the CPP.
Is the PAHO Strategic Fund a realistic channel for an Indian supplier in Belize?
Not without an upgrade. PAHO's published criteria admit only products authorised by WHO Prequalification, a stringent regulatory authority, or an American national regulatory authority of regional reference. A WHO-GMP certificate alone does not qualify, and CDSCO's WHO transitional listing is scoped to vaccines rather than medicines. Belize was recorded as a signed Strategic Fund participant in a 2017 annual report and no more recent named confirmation was found, so we make no claim about current volumes through that channel.
Technically Reviewed By: Maulik Sudani (Technical Expert) | Jignasu Sudani (Technical Expert), Farbe Firma Pvt Ltd, Gujarat, India.
Farbe Firma Pvt Ltd - WHO-GMP certified sterile injectable manufacturer and CDMO, Gujarat, India. Email director@farbefirma.org. Request a Quote / View Products / Blog
Comments